TY - JOUR
T1 - Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 β-lactamases at 2 hospitals in Taiwan
AU - Wu, Lii Tzu
AU - Wu, Hwa Jen
AU - Chung, Jing Gung
AU - Chuang, Yin Ching
AU - Cheng, Kuo Chen
AU - Yu, Wen-Liang
PY - 2006/2
Y1 - 2006/2
N2 - From February to June 2003, 111 clinical isolates of Proteus mirabilis were mainly isolated from patients with respiratory or urinary tract infections hospitalized at 3 district hospitals (A, B, C) in central Taiwan. Among them, 34 (30.6%) strains, isolated within 2 hospitals (A and B), exhibited nonsusceptibility to cefotaxime with significant reduction of MIC (≥3 log2 dilution) by the effect of clavulanic acid, which confirmed the phenotype of extended-spectrum β-lactamases (ESBLs). These ESBL producers were coresistant to gentamicin, isepamicin, and amikacin, but remained susceptible to ceftazidime (MIC, ≤0.5 μg/mL) and meropenem (MIC,
AB - From February to June 2003, 111 clinical isolates of Proteus mirabilis were mainly isolated from patients with respiratory or urinary tract infections hospitalized at 3 district hospitals (A, B, C) in central Taiwan. Among them, 34 (30.6%) strains, isolated within 2 hospitals (A and B), exhibited nonsusceptibility to cefotaxime with significant reduction of MIC (≥3 log2 dilution) by the effect of clavulanic acid, which confirmed the phenotype of extended-spectrum β-lactamases (ESBLs). These ESBL producers were coresistant to gentamicin, isepamicin, and amikacin, but remained susceptible to ceftazidime (MIC, ≤0.5 μg/mL) and meropenem (MIC,
KW - CTX-M
KW - Proteus mirabilis
KW - β-Lactamases
UR - https://www.scopus.com/pages/publications/31744449484
UR - https://www.scopus.com/pages/publications/31744449484#tab=citedBy
U2 - 10.1016/j.diagmicrobio.2005.09.005
DO - 10.1016/j.diagmicrobio.2005.09.005
M3 - Article
C2 - 16406185
AN - SCOPUS:31744449484
SN - 0732-8893
VL - 54
SP - 89
EP - 94
JO - Diagnostic Microbiology and Infectious Disease
JF - Diagnostic Microbiology and Infectious Disease
IS - 2
ER -